MARKET

ANAB

ANAB

Anaptysbio Inc
NASDAQ
50.24
+0.29
+0.58%
After Hours: 51.80 +1.56 +3.11% 19:10 02/10 EST
OPEN
49.72
PREV CLOSE
49.95
HIGH
51.37
LOW
48.95
VOLUME
236.01K
TURNOVER
--
52 WEEK HIGH
52.47
52 WEEK LOW
12.21
MARKET CAP
1.39B
P/E (TTM)
-17.8245
1D
5D
1M
3M
1Y
5Y
1D
Top Quant rated bullish small cap stocks among companies with high short interest
Seeking Alpha · 13h ago
Weekly Report: what happened at ANAB last week (0202-0206)?
Weekly Report · 1d ago
Is It Time To Reassess AnaptysBio (ANAB) After A 198% One-Year Share Price Surge
Simply Wall St · 4d ago
AnaptysBio to Split Biopharma Operations from Royalty Assets by 2026
Reuters · 5d ago
AnaptysBio kündigt Abspaltung von Biopharma-Geschäft und Royalty-Vermögenswerten bis Ende 2026 an
Reuters · 5d ago
Anaptys Announces Participation at Upcoming Investor Conferences
Barchart · 5d ago
Barclays Remains a Buy on AnaptysBio (ANAB)
TipRanks · 6d ago
Weekly Report: what happened at ANAB last week (0126-0130)?
Weekly Report · 02/02 10:04
More
About ANAB
AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. The Company’s lead program, Rosnilimab, is a depleter and agonist targeting PD-1+ T cells, is in a Phase IIb trial for the treatment of rheumatoid arthritis and in a Phase II trial for the treatment of ulcerative colitis. The Company’s pipeline also includes ANB033, a CD122 antagonist, and ANB101, a blood dendritic cell antigen 2 (BDCA2) modulator, in Phase I trials. It has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). Rosnilimab is an IgG1 antibody that directly targets PD-1+ T cells, resulting in their depletion or agonism, impacting pathogenic drivers of autoimmune and inflammatory diseases.

Webull offers AnaptysBio Inc stock information, including NASDAQ: ANAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANAB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ANAB stock methods without spending real money on the virtual paper trading platform.